ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

2019 ACR/ARP Annual Meeting

November 8-13, 2019. Atlanta, GA.

View by Number View by Title View Sessions
View by Date
Jump to:  [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z
  • Abstract Number: 709
    Structural Abnormalities of the Optic Nerve Head and Retinal Nerve Fiber Layer Using Optical Coherence Tomography in Patients with Systemic Sclerosis
  • Abstract Number: 2209
    Study of Vertebral Fracture Prevalence and Scanographic Bone Attenuation Coefficient of the First Lumbar Vertebra (SBAC-L1) in Patients with Rheumatoid Arthritis and Ankylosing Spondylitis vs. Controls
  • Abstract Number: 2321
    Subclinical Myocardial Dysfunction Assessed by Strain Imaging in Patients with Rheumatoid Arthritis and Spondyloarthritis
  • Abstract Number: 42
    Subclinical Oral Inflammation Is Common Across the Spectrum of Oral Findings in Rheumatoid Arthritis Patients, Whereas Porphyromonas Gingivalis Antibodies Are Primarily a Marker for Clinical Periodontitis
  • Abstract Number: 1815
    Subcutaneous or Intravenous Abatacept Monotherapy in Pediatric Patients with Polyarticular-Course JIA: Results from Two Phase III Trials
  • Abstract Number: 1236
    Subcutaneous or Oral Methotrexate Exposure and Response to Pegloticase in Uncontrolled Gout Patients in a Community Rheumatology Practice
  • Abstract Number: 1504
    Subcutaneous Secukinumab 150 Mg Provides Rapid and Sustained Relief in Total and Nocturnal Back Pains, Morning Stiffness, and Fatigue in Patients with Active Ankylosing Spondylitis over 4 Years
  • Abstract Number: 2756
    Subcutaneous Tanezumab versus NSAID for the Treatment of Osteoarthritis: Joint Safety Events in a Randomized, Double-Blind, Active-Controlled, 80-Week, Phase-3 Study
  • Abstract Number: 1302
    Subcutaneous Tanezumab vs NSAID for the Treatment of Osteoarthritis: Efficacy and General Safety Results from a Randomized, Double-Blind, Active-Controlled, 80-Week, Phase-3 Study
  • Abstract Number: 1875
    Subject Characteristics and Changes in Bone Mineral Density After Transitioning from Denosumab to Alendronate in the Denosumab Adherence Preference Satisfaction (DAPS) Study
  • Abstract Number: 1308
    Subject Enrichment Criteria for Phase 3 Studies of Lorecivivint (SM04690), a Potential Disease-Modifying Knee Osteoarthritis Drug: A Post Hoc Study on the Effects of Baseline Comorbid Pain and Joint Space Width on Patient-Reported Outcomes
  • Abstract Number: 2721
    Subjective and Objective Dyscognition in Adolescents with Juvenile Fibromyalgia Syndrome
  • Abstract Number: 2608
    Subsets in Systemic Sclerosis-ILD: Working Towards Consensus-Based Definitions
  • Abstract Number: 346
    Subtypes of Gout Based on Comorbidity Patterns Among Black Patients in the US General Population – Cluster Analysis of the National Health and Nutrition Examination Survey 2007-2016
  • Abstract Number: 1831
    Subtypes of Scleroderma Lung Involvement Associated with Burden of Disease and Outcomes
  • « Previous Page
  • 1
  • …
  • 165
  • 166
  • 167
  • 168
  • 169
  • …
  • 198
  • Next Page »
Jump to:  [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology